Year: 2025
Type: article
Abstract: Background The significance of the regional distribution of Aβ‐PET signal is not well established. We used data‐driven approaches to identify Aβ‐PET patterns and their clinicopathological associations in four independent cohorts (12,379 cognitively impaired patients). Methods We analysed multi‐tracer template‐space Aβ‐PET SUVR images to assign clinically impaired participants (MCI/Dementia) into groups based on their topography of Aβ‐PET binding. Using the IDEAS cohort, we applied independent component analysis to extract grey matter (GM) components of cortical and subcortical binding we then clustered patients by their score from these GM components using k‐means clustering. We then fit data from three independent cohorts to this model assessing associations between Aβ‐PET patterns and clinical impairment, APOE‐ε4, tau‐PET, and neuropathology (Table 1). Results We retained 11 GM components of Aβ‐PET and following k‐means clustering uncovered three clusters of participants in IDEAS (Figure 1a). One cluster had low GM Aβ‐PET binding (i.e., Aβ‐, n = 4729, mean CL=2), while the other two were Aβ+ with differences along a posterior‐anterior gradient: Aβ+ (posterior) ( n = 2484, mean CL=76), with predominant occipital binding, and Aβ+ (typical) ( n = 3148, mean CL=86). Applying new data to this model replicated this gradient in each independent dataset (Figure 1b). Contrasting clinical variables for the two Aβ+ clusters showed Aβ+ (posterior) patients were more clinically impaired than Aβ+ (typical) patients, had a lower proportion of APOE‐ε4 carriership, and had higher posterior tau‐PET (Figure 2a‐c). At autopsy, the Aβ+ (posterior) cluster presented with more severe cerebral amyloid angiopathy (CAA) (Figure 2d), but similar Thal and CERAD staging. There were no reliable differences in CL, age, and hippocampal volume (Figure 2e‐g). Conclusions We reliably assign patients into an Aβ+ (posterior) PET binding group uncovering consistent associations that suggests occipital regions should not be neglected in the appraisal of Aβ‐PET. Specifically, occipital Aβ+ PET binding may be a marker of CAA and more severe cognitive impairment.
Source: Alzheimer s & Dementia
Authors: Joseph Giorgio, Ganna Blazhenets, Jhony A. Mejía‐Perez, Daniel R. Schonhaut, Susan M. Landau, Stefania Pezzoli, Jennifer S. Yokoyama, Maria C. Carrillo, Lea T. Grinberg, William W. Seeley, Salvatore Spina, Liana G. Apostolova, Brad C. Dickerson, William J. Jagust, Gil D. Rabinovici, Renaud La Joie
Institutions: University of Newcastle Australia, University of California, Berkeley, University of California, San Francisco, Trinity College Dublin, Global Brain Health Institute, Alzheimer's Association, Indiana University Indianapolis, Indiana University School of Medicine, Harvard University, Massachusetts General Hospital
Language: English
Subfield: Psychiatry and Mental health
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $4,200
OpenAlex ID: W7117107917
FWCI:
Cites:
Cited by:
Related to:
